Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update

Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) was the recipient of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 224,000 shares, a decrease of 12.7% from the November 15th total of 256,500 shares. Based on an average daily trading volume, of 125,300 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.1% of the company's shares are short sold.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in shares of Aadi Bioscience during the 3rd quarter worth approximately $32,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Aadi Bioscience during the 2nd quarter worth approximately $37,000. Acuitas Investments LLC boosted its stake in shares of Aadi Bioscience by 10.8% during the 2nd quarter. Acuitas Investments LLC now owns 352,483 shares of the company's stock worth $515,000 after acquiring an additional 34,344 shares during the period. Finally, BML Capital Management LLC bought a new position in shares of Aadi Bioscience during the 3rd quarter worth approximately $4,120,000. 52.08% of the stock is currently owned by institutional investors.

Aadi Bioscience Price Performance

AADI stock remained flat at $2.41 during mid-day trading on Friday. The company's stock had a trading volume of 81,684 shares, compared to its average volume of 253,872. The stock's 50 day moving average is $2.17 and its 200 day moving average is $1.83. The company has a market capitalization of $59.40 million, a P/E ratio of -1.06 and a beta of 0.73. Aadi Bioscience has a 12-month low of $1.21 and a 12-month high of $5.49.

Aadi Bioscience (NASDAQ:AADI - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.46) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.46). The firm had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.55 million. Aadi Bioscience had a negative return on equity of 71.87% and a negative net margin of 246.06%. During the same period last year, the company earned ($0.60) earnings per share. As a group, equities analysts expect that Aadi Bioscience will post -1.78 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on AADI shares. HC Wainwright reaffirmed a "neutral" rating on shares of Aadi Bioscience in a research report on Wednesday, August 21st. Piper Sandler lowered Aadi Bioscience from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $5.00 to $1.75 in a research report on Tuesday, August 27th. Piper Sandler Companies lowered Aadi Bioscience from an "overweight" rating to a "neutral" rating and set a $1.75 price target on the stock. in a research report on Tuesday, August 27th. TD Cowen lowered Aadi Bioscience from a "buy" rating to a "hold" rating in a research report on Wednesday, August 21st. Finally, Jefferies Financial Group lowered Aadi Bioscience from a "buy" rating to a "hold" rating and dropped their price target for the stock from $11.00 to $1.50 in a research report on Wednesday, August 21st. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $1.67.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.